Radiation leukemogenesis: A proteomic approach

Experimental Hematology

Volumn 35, Issue 4 SUPPL., 2007, Pages 117-124

  Rithidech, Kanokporn Noy ^a   Honikel, Louise ^a   Simon, Sanford R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CLUSTERIN; GELSOLIN; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ELECTROSPRAY; GAMMA RADIATION; INTERMETHOD COMPARISON; LEUKEMIA; LINEAR ENERGY TRANSFER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; RADIATION DOSE; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ACUTE-PHASE PROTEINS; ANIMALS; GAMMA RAYS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, RADIATION-INDUCED; MICE; NEOPLASM PROTEINS; NEUTRONS; PROTEOME; TUMOR MARKERS, BIOLOGICAL; X-RAYS;

MUS;

EID: 33947327589     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.01.019     Document Type: Article

References (66)

1. UNSCARE: United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation (1993), United Nations, New York UN publication E.94.IX.2. UNSCARE, United Nations. 1993; UN publication E.94.IX.2
2. Pierce D.A., Shimizu Y., Preston D.L., Vaeth M., and Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 146 (1996) 1-27
3. Cronkite E, Bond, VP Radiation leukemic-prediction of low dose effects. National Cancer Institute Report, Contract Y01-CO 10712; 1988.
4. Hayata I., Ishihara T., Hirashima K., Sado T., and Yamagiwa J. Partial deletion of chromosome No. 2 in myelocytic leukemias of irradiated C3H/He and RFM mice. J Natl Cancer Inst 63 (1979) 843-848
5. Mole R.H., Papworth D.G., and Corp M.J. The dose-response for x-ray induction of myeloid leukemia in male CBA/H mice. Br J Cancer 47 (1983) 285-291
6. Boice Jr. J.D. Cancer following irradiation in childhood and adolescence. Med Pediatr Oncol Suppl 1 (1996) 29-34
7. Noshchenko A.G., Zamostyan P.V., Bondar O.Y., and Drozdova V.D. Radiation-induced leukemia risk among those aged 0-20 at the time of the Chernobyl accident: a case-control study in the Ukraine. Int J Cancer 99 (2002) 609-618
8. Court-Brown W.M., and Doll R. Leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis. Spec Rep Ser Med Res Counc (G B) 295 (1957) 1-135
9. Larson R.A., and Le Beau M.M. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact 153-154 (2005) 187-195
10. Deininger M.W., Bose S., Gora-Tybor J., Yan X.H., Goldman J.M., and Melo J.V. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res 58 (1998) 421-425
11. Hromas R., Shopnick R., Jumean H.G., Bowers C., Varella-Garcia M., and Richkind K. A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95 (2000) 4011-4013
12. Klymenko S., Trott K., Atkinson M., et al. Aml1 gene rearrangements and mutations in radiation-associated acute myeloid leukemia and myelodysplastic syndromes. J Radiat Res 46 (2005) 249-255
13. Bouffler S.D., Breckon G., and Cox R. Chromosomal mechanisms in murine radiation acute myeloid leukaemogenesis. Carcinogenesis 17 (1996) 655-659
14. Rithidech K.N., Cronkite E.P., and Bond V.P. Advantages of the CBA mouse in leukemogenesis research. Blood Cells Mol Dis 25 (1999) 38-45
15. Boulton E., Cole C., Knight A., Cleary H., Snowden R., and Plumb M. Low-penetrance genetic susceptibility and resistance loci implicated in the relative risk for radiation-induced acute myeloid leukemia in mice. Blood 101 (2003) 2349-2354
16. Rithidech K.N., Bond V.P., Cronkite E.P., and Thompson M.H. A specific chromosomal deletion in murine leukemic cells induced by radiation with different qualities. Exp Hematol 21 (1993) 427-431
17. Boorman G.A., Rafferty C.N., Ward J.M., and Sills R.C. Leukemia and lymphoma incidence in rodents exposed to low-frequency magnetic fields. Radiat Res 153 (2000) 627-636
18. Cronkite E.P., Bond V.P., Carsten A.L., Inoue T., Miller M.E., and Bullis J.E. Effects of low level radiation upon the hematopoietic stem cell: implications for leukemogenesis. Radiat Environ Biophys 26 (1987) 103-114
19. Boulton E., Cleary H., Papworth D., and Plumb M. Susceptibility to radiation-induced leukaemia/lymphoma is genetically separable from sensitivity to radiation-induced genomic instability. Int J Radiat Biol 77 (2001) 21-29
20. Okumoto M., Nishikawa R., Iwai M., et al. Lack of evidence for the involvement of type-C and type-B retroviruses in radiation leukemogenesis of NFS mice. Radiat Res 121 (1990) 267-273
21. Rithidech K., Bond V.P., Cronkite E.P., Thompson M.H., and Bullis J.E. Hypermutability of mouse chromosome 2 during the development of x-ray-induced murine myeloid leukemia. Proc Natl Acad Sci U S A 92 (1995) 1152-1156
22. Rithidech K.N., Dunn J.J., Gordon C.R., Cronkite E.P., and Bond V.P. N-ras mutations in radiation-induced murine leukemic cells. Blood Cells Mol Dis 22 (1996) 271-280
23. Rithidech K.N., Dunn J.J., Gordon C.R., Cronkite E.P., and Bond V.P. Evidence for an uncommon microsatellite instability on mouse chromosomes 2 and 4 and its possible role in radiation leukemogenesis. Blood Cells Mol Dis 23 (1997) 99-109
24. Rithidech K., Dunn J.J., Bond V.P., Gordon C.R., and Cronkite E.P. Characterization of genetic instability in radiation- and benzene-induced murine acute leukemia. Mutat Res 428 (1999) 33-39
25. Rithidech K., Gordon C.R., and Cronkite E.P. Telomerase activity in mouse myeloid leukemic cells and in cells from normal hematopoietic systems. Blood Cells Mol Dis 27 (2001) 496-504
26. Rithidech K., Dunn J.J., Roe B.A., Gordon C.R., and Cronkite E.P. Evidence for two commonly deleted regions on mouse chromosome 2 in gamma ray-induced acute myeloid leukemic cells. Exp Hematol 30 (2002) 564-570
27. Haran-Ghera N., Resnitzky P., Krautghamer R., and Tartakovsky B. Multiphase process involved in radiation induced murine AML. Leukemia 6 suppl 3 (1992) 123S-125S
28. Clark D.J., Meijne E.I., Bouffler S.D., et al. Microsatellite analysis of recurrent chromosome 2 deletions in acute myeloid leukaemia induced by radiation in F1 hybrid mice. Genes Chromosomes Cancer 16 (1996) 238-246
29. Silver A., Moody J., Dunford R., et al. Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12. Genes Chromosomes Cancer 24 (1999) 95-104
30. Finnon R., Moody J., Meijne E., et al. A major breakpoint cluster domain in murine radiation-induced acute myeloid leukemia. Mol Carcinog 34 (2002) 64-71
31. Alexander B.J., Rasko J.E., Morahan G., and Cook W.D. Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia. Leukemia 9 (1995) 2009-2015
32. Rowen L., Young J., Birditt B., et al. Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 79 (2002) 587-597
33. Dohner K., Tobis K., Bischof T., et al. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood 102 (2003) 3850-3851
34. Mueller B.U., Pabst T., Osato M., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (2002) 998-1007
35. Lamandin C., Sagot C., Roumier C., et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?. Blood 100 (2002) 4680
36. Suraweera N., Meijne E., Moody J., et al. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene 24 (2005) 3678-3683
37. Calvo K.R., Liotta L.A., and Petricoin E.F. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 25 (2005) 107-125
38. Stanley B.A., Gundry R.L., Cotter R.J., and Van Eyk J.E. Heart disease, clinical proteomics and mass spectrometry. Dis Markers 20 (2004) 167-178
39. Davidsson P., and Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 21 (2005) 81-92
40. Cui J.-W., Wang J., He K., et al. Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 10 (2004) 6887-6896
41. Kwak J.-Y., Ma T.-Z., Yoo M.-J., et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 32 (2004) 836-842
42. Lopez-Pedrera C., Villalba J.M., Siendones E., et al. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 6 suppl 1 (2006) S293-S299
43. In: Kinter M., and Sherman N.E. (Eds). Protein Sequencing and Identification Using Tandem Mass Spectrometry (2000), Wiley Interscience, Hoboken, NJ
44. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1 (2002) 845-867
45. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol (Lond) 563 (2005) 23-60
46. Klokov D., Criswell T., Leskov K.S., Araki S., Mayo L., and Boothman D.A. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res 568 (2004) 97-110
47. Pajak B., and Orzechowski A. Clusterin: the missing link in the calcium-dependent resistance of cancer cells to apoptogenic stimuli. Postepy Hig Med Dosw (Online) 60 (2006) 45-51
48. Shannan B., Seifert M., Leskov K., et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13 (2006) 12-19
49. Bhat V.B., Choi M.H., Wishnok J.S., and Tannenbaum S.R. Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res 4 (2005) 1814-1825
50. Bakker W.W., Borghuis T., Harmsen M.C., et al. Protease activity of plasma hemopexin. Kidney Int 68 (2005) 603-610
51. Misra U.K., Deedwania R., and Pizzo S.V. Activation and cross-talk between Akt, NF-{kappa}B, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 281 (2006) 13694-13707
52. Bijl M., Bootsma H., van der Geld Y., Limburg P.C., Kallenberg C.G.M., and van Rijswijk M.H. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 63 (2004) 831-835
53. Levo Y., Wollner S., and Treves A.J. Serum amyloid P-component levels in patients with malignancy. Scand J Immunol 24 (1986) 147-151
54. Barter P.J., Nicholls S., Rye K.-A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
55. Baroni S., Scribano D., Pagano L., Zuppi C., Leone G., and Giardina B. Lipids and lipoproteins in acute lymphoblastic leukemia (ALL). Leuk Res 18 (1994) 643-644
56. Pandita T.K., Higashikubo R., and Hunt C.R. HSP70 and genomic stability. Cell Cycle 3 (2004) 591-592
57. Guo F., Sigua C., Bali P., et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105 (2005) 1246-1255
58. Thomas X., Campos L., Mounier C., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29 (2005) 1049-1058
59. Duval A., Olaru D., Campos L., Flandrin P., Nadal N., and Guyotat D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica 91 (2006) 713-714
60. Sun H.Q., Yamamoto M., Mejillano M., and Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274 (1999) 33179-33182
61. Tanaka H., Shirkoohi R., Nakagawa K., et al. siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118 (2006) 1680-1691
62. Pilz A., Moseley H., Peters J., and Abbott C. Comparative mapping of mouse chromosome 2 and human chromosome 9q: the genes for gelsolin and dopamine beta-hydroxylase map to mouse chromosome 2. Genomics 12 (1992) 715-719
63. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
64. Shtivelman E., Lifshitz B., Gale R.P., and Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
65. Oyarzo M.P., Lin P., Glassman A., Bueso-Ramos C.E., Luthra R., and Medeiros L.J. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 122 (2004) 348-358
66. Rowley J.D., and Potter D. Chromosomal banding patterns in acute nonlymphocytic leukemia. Blood 47 (1976) 705-721